Paul Tudor Jones’s Amylyx Pharmaceuticals AMLX Stock Holding History

Paul Tudor Jones’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$636K	Buy	35,410 +4,076	+13%	+$63K	﹤0.01%	2695
2026 Q1	$436K	Buy	31,334 +8,932	+40%	+$126K	﹤0.01%	2903
2025 Q4	$271K	Buy	+22,402	New	+$304K	﹤0.01%	3116
2025 Q3	–	Sell	-12,073	Closed	-$77.4K	–	3321
2025 Q2	$77.4K	Sell	12,073 -21,355	-64%	-$104K	﹤0.01%	3160
2025 Q1	$118K	Sell	33,428 -259	-0.8%	-$922	﹤0.01%	2929
2024 Q4	$127K	Buy	+33,687	New	+$159K	﹤0.01%	2896
2024 Q2	–	Sell	-12,753	Closed	-$36.2K	–	2288
2024 Q1	$36.2K	Sell	12,753 -20,899	-62%	-$273K	﹤0.01%	2124
2023 Q4	$495K	Buy	33,652 +6,293	+23%	+$96.5K	﹤0.01%	1801
2023 Q3	$501K	Sell	27,359 -32,256	-54%	-$682K	0.01%	1680
2023 Q2	$1.29M	Buy	59,615 +22,051	+59%	+$596K	0.02%	1162
2023 Q1	$1.1M	Buy	37,564 +1,567	+4%	+$54.4K	0.02%	1137
2022 Q4	$1.33M	Buy	35,997 +19,859	+123%	+$705K	0.03%	895
2022 Q3	$454K	Buy	+16,138	New	+$403K	0.01%	1468

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Paul Tudor Jones's AMLX Position: Q2 2026 in Review

Paul Tudor Jones increased its Amylyx Pharmaceuticals (AMLX) stake by 13% in Q2 2026, buying an estimated $63K and bringing the position to 35,410 shares worth $636K. The position accounts for ﹤0.01% of the portfolio, ranked #2695.

Paul Tudor Jones first reported a position in AMLX in Q3 2022 and has held it in 13 quarters since. The position peaked at $1.33M in Q4 2022. 205 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Paul Tudor Jones held 35,410 shares of Amylyx Pharmaceuticals worth $636K as of Q2 2026.
Paul Tudor Jones bought 4,076 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $63K.
Amylyx Pharmaceuticals made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #2695 holding.
Paul Tudor Jones first reported a position in Amylyx Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
Paul Tudor Jones's Amylyx Pharmaceuticals position peaked at $1.33M in Q4 2022.
205 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.